Table 8.
Association Between Anthracycline Chemotherapy vs Nonanthracycline Chemotherapy and HF Hospitalization Among Patients With Pre-Existing HF
| Anthracycline Use vs Nonanthracycline | HF Admissions |
||
|---|---|---|---|
| All Patients | Early Stage | Advanced Stage | |
| Cohort sample size | 245 | 87 | 150 |
| Number of events | 135 | 46 | 84 |
| Unadjusteda | 0.99 (0.71-1.39) | 0.93 (0.53-1.63) | 0.95 (0.62-1.46) |
| Model A (adjusted for clinical variables)b | 1.07 (0.76-1.51) | 0.73 (0.39-1.38) | 0.98 (0.62-1.55) |
Values are HR (95% CI). Cox proportional hazards model of time to first HF admission accounting for the competing risk of death.
HF = heart failure.
a
Unadjusted includes anthracycline use within the first 90 days (time varying) as the only independent variable.
b
Adjusted for age, sex, race, Hispanic ethnicity, diabetes, any prior cancer diagnosis, chronic bronchitis or emphysema, dementia, and moderate or severe renal dysfunction. The model including all stages was additionally adjusted for advanced stage (III or IV vs I or II).